Which stocks are experiencing notable movement on Monday? Looking for insights into the US markets one hour before the close of the markets on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
FDA Eases Access To Life-Saving Gene Therapies For Blood Cancers FDA lifts REMS for approved CAR-T therapies, easing hospital restrictions and signaling broader future access in oncology and autoimmune treatment.
The FDA Shake-Up Continues, And Could Impact Genetic Medicines Nicole Verdun and Rachael Anatol were placed on administration leave without explanation.
Gilead Ups 2025 Outlook, Eyes Lenacapavir Launch For HIV Prevention Gilead reported Q4 adjusted EPS of $1.90, exceeding estimates, with HIV sales up 16%. The company raised guidance and expects a key HIV drug launch in 2025.
Arcellx Stock Earns 82 Relative Strength Rating Arcellx stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 79 to 82.
Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients Arcellx's Phase 2 trial of anito-cel in relapsed multiple myeloma reveals high response rates and manageable safety, with durable patient outcomes.
ACLX Stock Earnings: Arcellx Beats EPS, Beats Revenue for Q2 2024 ACLX stock results show that Arcellx beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals Biotech stocks are on the verge of a comeback after a period of underperformance amid a wave of FDA approvals.
Arcellx Stock Earns Relative Strength Rating Upgrade One key metric to look for in a stock is an 80-plus Relative Strength Rating. Arcellx stock cleared that benchmark Friday, jumping to 83.
